Drug Approval | December 20, 2023
Briefs: Aurobindo Pharma and Granules Pharmaceuticals
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Laurus Synthesis receives Form 483 with 5 observations from USFDA
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Prior to joining Alembic, he was working with Lupin Limited for more than 11 years
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Lack of technology transfer stands out as a formidable barrier
Lincoln Pharmaceuticals has reported total income of Rs. 164.68 crores during the period ended September 30, 2023
Subscribe To Our Newsletter & Stay Updated
